Welcome to our dedicated page for KIORA PHARMACEUTICALS SEC filings (Ticker: KPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiora Pharmaceuticals filings document a clinical-stage ophthalmology issuer focused on small-molecule programs for retinal disease. Current disclosures cover results of operations and financial condition, research-and-development progress for KIO-301 and KIO-104, collaboration reimbursements, and clinical or regulatory updates tied to the company’s development pipeline.
Material-event reports also record securities purchase agreements, common stock, pre-funded warrants and Tranche A warrants issued in private placements, along with executive changes. Proxy materials address board governance, executive compensation, equity awards, shareholder voting matters and related risk-factor disclosures for a Nasdaq-listed Delaware corporation.
Kiora Pharmaceuticals director Aron Shapiro received a grant of stock options as part of equity compensation. The award covers 25,000 options for Common Stock at an exercise price of $2.63 per share, becomes fully exercisable on June 10, 2027, and expires on June 10, 2036.
Kiora Pharmaceuticals director Erin Parsons reported a compensation-related stock option grant. She received options to buy 25,000 shares of Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options will become fully exercisable on June 10, 2027 and expire on June 10, 2036. After this grant, Parsons holds options covering 25,000 shares. This is an award, not an open-market purchase or sale of stock.
Kiora Pharmaceuticals director David Hollander received a grant of stock options as compensation. He was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, issued under the company’s 2024 Equity Incentive Plan.
The options will become fully exercisable on June 10, 2027 and are scheduled to expire on June 10, 2036 if not exercised. After this grant, Hollander holds 25,000 stock options directly, giving him potential future ownership if the options are exercised.
Kiora Pharmaceuticals director Lisa Walters-Hoffert received a grant of stock options as part of her compensation. She was awarded 25,000 options to buy Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options were granted at no cost and relate to 25,000 underlying shares of common stock. They will become fully exercisable on June 10, 2027 and will expire on June 10, 2036 if not exercised. After this grant, she holds 25,000 options directly, and the filing reports no open-market purchases or sales.
Kiora Pharmaceuticals director Praveen Tyle received a grant of stock options as equity compensation. The award covers options on 40,000 shares of common stock at an exercise price of $2.63 per share under the 2024 Equity Incentive Plan.
The options become fully exercisable on June 10, 2027 and expire on June 10, 2036. Following this grant, Tyle holds options on 40,000 shares directly, with no open-market buying or selling reported in this filing.
Kiora Pharmaceuticals, Inc. reported results from its 2026 annual meeting of stockholders. Stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the shares of common stock authorized for issuance under the plan by 1,500,000 shares.
Three Class II directors — Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle, Ph.D. — were re-elected for terms running until the 2029 annual meeting, with over 1,029,000 votes cast for each nominee. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
Haskell & White LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026, receiving 2,358,943 votes for, 5,403 against, and 1,983 abstentions.
Kiora Pharmaceuticals, Inc. is registering for resale up to 11,797,088 shares of Common Stock, consisting of (i) 438,471 shares issued in a private placement, (ii) 1,527,710 shares underlying pre-funded warrants, (iii) 7,864,726 shares underlying Tranche A-1 warrants, and (iv) 1,966,181 shares underlying Tranche A-2 warrants.
The shares are being registered for resale by the selling stockholders named in the prospectus; the company is not offering any shares for its own account and will receive no proceeds from resale transactions, although it will receive proceeds if warrants are exercised for cash. The prospectus notes that the registrable shares represent approximately 72.7% of outstanding common stock as of May 14, 2026 (calculated assuming full exercise of the registered warrants and without applying beneficial ownership limits). Selling holders may sell from time to time by public or private transactions under the plan of distribution described in the prospectus.
Kiora Pharmaceuticals, Inc. is registering 11,797,088 shares of Common Stock for resale by selling stockholders.
The registration covers (i) 438,471 shares issued in a Private Placement, (ii) 1,527,710 shares underlying pre-funded warrants, (iii) 7,864,726 shares underlying Tranche A-1 warrants, and (iv) 1,966,181 shares underlying Tranche A-2 warrants. The Company is not offering any shares for its own account and will receive no proceeds from resales; however, the Company would receive proceeds from any warrant cash exercises. The prospectus states that the registered securities represent approximately 72.7% of outstanding common stock as of May 14, 2026 after giving effect to the registered underlying shares. The resale may occur from time to time through public or private transactions as described in the Plan of Distribution.
Kiora Pharmaceuticals, Inc. reports that Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 438,469 shares of common stock as of March 31, 2026. The filing states those shares represent 9.99% of the outstanding common stock and that the 438,469 shares include shares issuable upon exercise of convertible securities within sixty days. The reporting persons disclose shared voting and dispositive power over the 438,469 shares. A fund advised by Nantahala, BLACKWELL PARTNERS LLC - SERIES A, is identified as having the right to receive dividends or sale proceeds on more than 5% of those shares.